A case of FDG-PET positive lung cancer with hilar lymph node metastases, which showed false negative FDG-PET findings

Japanese Journal of Lung Cancer

Volumn 45, Issue 4, 2005, Pages 381-386

  Nezu, Kenji ^a,b   Sato, Yukitoshi ^a,c   Matsui, Yoshio ^a   Okumura, Sakae ^a   Nakagawa, Ken ^a   Ishikawa, Yuichi ^c  

^a Cancer Institute Hospital   (Japan)

^b EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c CANCER INSTITUTE   (Japan)

Author keywords

Adenocarcinoma; Clinical stage; FDG PET; Lung cancer

Indexed keywords

FLUORODEOXYGLUCOSE; MUCIN;

ADRENAL GLAND; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG HILUS; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY;

EID: 25144447411     PISSN: 03869628     EISSN: None     Source Type: Journal    
DOI: 10.2482/haigan.45.381     Document Type: Article

References (15)

1. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG-PET literature. J Nucl Med. 2001;42: 1-93.
2. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995;60:1573-1582.
3. Bury T, Dowlati A, Paulus P, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J. 1997; 10:2529-2534.
4. Coleman RE. PET in lung cancer staging. J Nucl Med. 2001;45:231-234.
5. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1393.
6. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18) F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001;19:111-118.
7. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142-2149.
8. Hicks RJ, Kalff V, MacManus MP, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-1604.
9. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG-PET imaging is negative in bronchiolo-alveolar lung carcinoma. J Nucl Med. 1998;39:1016-1020.
10. Higashi K, Ueda Y, Ayabe K, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun. 2000;21:707-714.
11. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40: 1784-1791.
12. Berger KL, Nicholson SA, Dehdashti F, et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Am J Roentgenol. 2000;174:1005-1008.